EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics

Shubham Roy, Neelanjana Bag, Souravi Bardhan, Ikram Hasan, Bing Guo

Advanced Drug Delivery Reviews · 2023-06 · 197 · 114821

DOI: 10.1016/j.addr.2023.114821 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-06. Verfasst von Shubham Roy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Flexible Printed Electronics Technology and School of Science, Harbin Institute of Technology, Shenzhen 518055, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 183-mal zitiert (Crossref) und nennt 265 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluorescence imaging in the second near-infrared window (NIR-II) has become a prevalent choice owing to its appealing advantages like deep penetration depth, low autofluorescence, decent spatiotemporal resolution, and a high signal-to-background ratio. This would expedite the innovation of NIR-II imaging-guided drug delivery (IGDD) paradigms for the improvement of the prognosis of patients with tumors. This work systematically reviews the recent progress of such NIR-II IGDD-mediated cancer therapeutics and collectively brings its essence to the readers. Special care has been taken to assess their performances based on their design approach, such as enhancing their drug loading and triggering release, designing intrinsic and extrinsic fluorophores, and/ or overcoming biological barriers. Besides, the state-of-the-art NIR-II IGDD platforms for different therapies like chemo-, photodynamic, photothermal, chemodynamic, immuno-, ion channel, gas-therapies, and multiple functions such as stimulus-responsive imaging and therapy, and monitoring of drug release and therapeutic response, have been updated. In addition, for boosting theranostic outcomes and clinical translation, the innovation directions of NIR-II IGDD platforms are summarized, including renal-clearable, biodegradable, sub-cellular targeting, and/or afterglow, chemiluminescence, X-ray excitable NIR-IGDD, and even cell therapy. This review will propel new directions for safe and efficient NIR-II fluorescence-mediated anticancer drug delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsNanoparticlesHumansPrecision MedicineTheranostic NanomedicineOptical Imaging

Stichwörter der Autor:innen

Cancer theranosticsDiagnosticsImage-guided drug deliveryNIR-II biowindowTherapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Shenzhen Key Laboratory of Flexible Printed Electronics Technology and School of Science, Harbin Institute of Technology, Shenzhen 518055, China.
  • Department of Physics, Jadavpur University, Kolkata 700032, India.
  • School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, Guangdong 518060, China.
  • Shenzhen Key Laboratory of Flexible Printed Electronics Technology and School of Science, Harbin Institute of Technology, Shenzhen 518055, China. Electronic address: guobing2020@hit.edu.cn.

Zitieren

APA

Roy, S., Bag, N., Bardhan, S., Hasan, I., & Guo, B. (2023). Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics. Advanced Drug Delivery Reviews, 197, 114821. https://doi.org/10.1016/j.addr.2023.114821

Vancouver

Roy S, Bag N, Bardhan S, Hasan I, Guo B. Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics. Advanced Drug Delivery Reviews. 2023;197:114821. doi:10.1016/j.addr.2023.114821

BibTeX
@article{Roy2023,
  author = {Roy, Shubham and Bag, Neelanjana and Bardhan, Souravi and Hasan, Ikram and Guo, Bing},
  title = {Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics},
  journal = {Advanced Drug Delivery Reviews},
  year = {2023},
  volume = {197},
  pages = {114821},
  doi = {10.1016/j.addr.2023.114821}
}
Kostenlos starten →